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Abstract: The highly heterogeneous clinical course of human prostate cancer has prompted the
development of multiple RNA biomarkers and diagnostic tools to predict outcome for individual
patients. Biomarker discovery is often unstable with, for example, small changes in discovery dataset
configuration resulting in large alterations in biomarker composition. Our hypothesis, which forms
the basis of this current study, is that highly significant overlaps occurring between gene signatures
obtained using entirely different approaches indicate genes fundamental for controlling cancer
progression. For prostate cancer, we found two sets of signatures that had significant overlaps
suggesting important genes (p < 10−34 for paired overlaps, hypergeometrical test). These overlapping
signatures defined a core set of genes linking hormone signalling (HES6-AR), cell cycle progression
(Prolaris) and a molecular subgroup of patients (PCS1) derived by Non Negative Matrix Factorization
(NNMF) of control pathways, together designated as SIG-HES6. The second set (designated
SIG-DESNT) consisted of the DESNT diagnostic signature and a second NNMF signature PCS3.
Stratifications using SIG-HES6 (HES6, PCS1, Prolaris) and SIG-DESNT (DESNT) classifiers frequently
detected the same individual high-risk cancers, indicating that the underlying mechanisms associated
with SIG-HES6 and SIG-DESNT may act together to promote aggressive cancer development. We show
that the use of combinations of a SIG-HES6 signature together with DESNT substantially increases
the ability to predict poor outcome, and we propose a model for prostate cancer development
involving co-operation between the SIG-HES6 and SIG-DESNT pathways that has implication for
therapeutic design.
Keywords: prostate cancer; prognostic signature; diagnostic signature; biomarkers; cancer
progression; aggressive cancer
1. Introduction
A major problem in management of human prostate cancer is the high variability in its clinical
course making prediction of outcome at the time of diagnosis or following radical therapy extremely
difficult [1,2]. A critical challenge is to improve prediction of outcome beyond the use of standard clinical
predictors including D’Amico stratification and CAPRA score [3]. For prostate cancer, the development
of expression-based prognostic biomarkers has proven very fruitful with over 20 predictive signatures
and classifications reported. Many signatures were derived using supervised approaches involving
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comparisons of aggressive and nonaggressive disease [4–17]. Several biomarkers represent particular
biological functions [18–22]. For example, the Prolaris biomarker [19] contains genes known to be
involved in controlling transition through the cell cycle.
Unsupervised approaches may also be used for classification and biomarker identification [23–26].
We have used an unsupervised mathematical approach called Latent Process Decomposition (LPD) that
takes into account the issue of heterogeneity within individual prostate samples to identify a new poor
prognosis category of prostate cancer called DESNT [23,27]. In an alternative unsupervised approach,
the status of control pathways deduced from expression datasets was analysed using Non-Negative
Matrix Factorisation (NNMF), leading to the identification of a poor prognosis category called PSC1 [26].
The presence of somatic copy number alterations, sometimes linked to the expression of genes within
regions of alteration, has also be utilised for biomarker identification [28].
An interesting feature of biomarkers discovery involving comparisons of expression linked to
different clinical states are the small overlaps between different predictive gene lists for the same
biological endpoint. This observation, and its underlying causes, are well documented for human
breast cancer [29–31]. A series of studies demonstrated that the lack of overlap cannot be simply be
attributed to trivial reasons such as the use of different patient cohorts, different detection technologies,
and different analytical methods. This is illustrated by the work of Ein-Dor et al. [29], who repeated
the analysis performed by van’t Veer et al. [32] during their derivation of the Mammaprint 70-gene
predictive signature for breast cancer outcome. Using transcriptome data from many subsets of
training samples that were selected from the complete van’t Veer et al. dataset, they demonstrated
that multiple different but equally predictive 70-gene signatures could be derived. They noted that
for many hundreds of individual genes, the correlation with survival had intermediate predictive
values and that the differences between values were very small. The relative ranking of genes
changed dramatically when slightly different training sets were used, leading to the selection of poorly
overlapping predictive signatures.
In the current study, we wished to examine the relationship between biomarker signatures that
were derived using a variety different approaches. Our hypothesis is that the progression of prostate
cancer occurs via one or a small number of underlying biological process and that the significant
overlaps between prognostic signatures obtained by independent methods of discovery and using
different datasets may indicate sampling from genes fundamental for controlling cancer progression.
2. Materials and Methods
2.1. The You et al. Discovery Cohort (DISC)
To repeat the work of You et al., we complied and normalised expression profiles from the
same set of 38 public datasets as in You et al. [26] (DISC cohort) except that we did not include the
ArrayExpress dataset E-SMDB-2486, which contains the same samples as the GEO dataset GSE3933.
Where available, the raw data has been retrieved from GEO and ArrayExpress repositories, otherwise
the provided normalised data from the datasets were used. For the TCGA dataset, the RNA-seq
level 3 raw expression data have been downloaded from the TCGA data portal. Only the 217 TCGA
samples uploaded before 24/04/2013 have been included in the DISC cohort. Two-channel microarray
datasets have been internally normalised using the loess method [33] and across arrays using the
quantile method [34]—both implemented in the limma R package [35]. One-channel microarrays have
been normalised across arrays using the RMA algorithm [36] implemented in either the affy [37] or
oligo [38] R packages, depending on the microarray platform. RNA-seq raw read counts have been
processed using the variance stabilizing transformation implemented in DESeq2 [39]. For datasets that
contained samples from more than one platform, samples from each platform have been normalised
separately. The probes from the three platforms used in the GSE6919 dataset have been merged
into a single sample, for each patient id. Probes from each platform have been annotated to
Entrez gene identifiers using the corresponding Bioconductor annotation packages, if available;
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otherwise the probe identifiers have been converted to entrez ids using the SOURCE interface
(http://source-search.princeton.edu/help/SOURCE/resultsBatchHelp.html), Agilent annotation lists or
biomaRt package [40]. The Multi-Dimensional-Scaling (MDS) decomposition of the expression profiles
of the DISC cohort are shown in Figure S1.
For each dataset, duplicate probes for each Entrez Id have been removed, keeping only the probe
with the highest mean expression across samples. The gene intensities have been centred by subtracting
the median across samples. The DISC cohort has been then assembled by matching the Entrez Ids,
resulting in a cohort of 2707 samples and 32,832 genes. Subsequently, the primary tissue samples
without an associated Gleason score, have been removed, resulting in a set of 1381 samples. To remove
dataset and platform-specific effects, the data was median-centered and the quantile normalised (MCQ)
as described in You et al. [26]. Potential differences compared to the original protocol of You et al. may
arise because of the removal of sample duplication and the use of the most probable approach when
the published protocol was not completely clear.
2.2. Validation Datasets
Four publicly available transcriptome microarray datasets derived from prostatectomy samples
from men with prostate cancer were used as a validation dataset and are referred to as: Memorial
Sloan Kettering Cancer Centre (MSKCC) [41], CancerMap [23], CamCap [24], and SWD [42]. From the
MSKCC dataset, only prostatectomy specimens were used, both in the derivation of the original
DESNT classification and for validation analyses in the current studies. The CamCap dataset was
produced by combining two Illumina HumanHT-12 V4.0 expression beadchip datasets (GEO: GSE70768
and GSE70769) obtained from two prostatectomy series (Cambridge and Stockholm). The original
CamCap [24] and CancerMap [23] datasets have 40 patients in common and thus 20 of the common
samples were excluded at random from each dataset. Each Affymetrix Exon microarray dataset was
normalised using the RMA algorithm [36] implemented in the Affymetrix Expression Console software.
For CamCap and Stephenson, previous normalised values were used. The ComBat algorithm from the
sva R package and quantile transformation, was used to mitigate series-specific effects.
2.3. Replicating You et al. Analysis
2.3.1. Pathway Activation Z-Score
For a given pathway and a given sample, the pathway activation score has been calculated as





where XtS is the mean expression level of the genes in pathway S and sample t, Xt is the mean
expression level of all genes in sample t, σt is the standard deviation of all genes in sample t, and |S| is
the number of genes in the set S.
2.3.2. Non-Negative Matrix Factorization
Non-negative matrix factorization (NNMF) algorithm implemented in the NNMF R package [44]
was used with default parameters.
2.3.3. NNMF Random Forest Classifier
A random forest classifier was trained on the DISC cohort to discriminate between the three
NNMF clusters, using as features the 14-pathway z-scores calculated as described above. The model
has been built using the implementation from the randomForest R package. The number of trees has
been set to 5001, and samples within each class are down-sampled to the frequency of the smallest
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class; otherwise, the default settings have been used. The model obtained an out-of-bag (OOB) overall
accuracy of 92.5%, and a per-class AUC of 0.98–0.99 (Figure S2a–c).
2.4. Replicating the Ramos-Montoya Classifier
To reproduce the Ramos-Montoya classification, a random forest model has been trained on the
MSKCC dataset. It uses as training labels the assignment of the MSKCC samples into two classes
available in Figure 4a of Ramos-Montoya et al. [22] and as features, the 222 genes in the Ramos-Montoya
signature. The model has been built using the randomForest R package. The number of tress has been
set to 5001, and samples within each class are down-sampled to the frequency of the smallest class;
otherwise, the default settings have been used. The model obtained an out-of-bag (OOB) accuracy of
92.67%, and a per-class AUC of 0.99 (Figure S2d).
2.5. Replicating the Prolaris Classifier
For the Prolaris classification on a given sample, a score is calculated by averaging the
within-sample z-score normalised expression of the 31 CCP genes [19]. For a given dataset, the top
25% of patients with the highest score are considered high-risk.
2.6. LPD (Latent Process Decomposition) DESNT
LPD [45,46] is an unsupervised Bayesian approach which breaks down (decomposes) each sample
into component sub-elements (signatures). Each signature is a representative gene expression pattern.
LPD is able to classify complex data based on the relative representation of these signatures in each
sample and can objectively assess the most likely number of signatures. The approach can take into
account the heterogeneous composition of individual prostate cancer samples. The LPD procedure
was carried out exactly as described previously [23,27]. The OAS-LPD algorithm is a modified version
of the LPD algorithm in which new sample(s) are decomposed into LPD signatures, without retraining
the model (i.e., without re-estimating the model parameters µgk, σ2gk, and α). OAS-LPD was carried
out exactly as previously described [27].
2.7. Statistical Analysis
The statistical analyses have been carried out in R version 3.3.2. For determining
the statistical significance of intersection between two sets of genes, the hypergeometrical
test has been used. Genes were defined as differentially expressed if the FDR-adjusted
p-value < 0.001 and a fold change >1.4 and identified for each comparison using a moderated
t-test implemented in the limma R package. Gene set enrichment analysis was performed
using the Fast Gene Set Enrichment Analysis Bioconductor package [47] using 10,000 permutations.
Survival analyses were performed using the log-rank test and Kaplan–Meier estimator, as implemented
in the survival R package with biochemical recurrence after prostatectomy as the end point. All survival
analyses were performed on the combined CancerMap, CamCap and MSKCC cancer datasets (n = 482)
unless otherwise stated.
3. Results
3.1. Relationships between Prostate Cancer Signatures
As a starting point for this study, we compared 25 published mRNA expression signatures derived
to predict aggressive human prostate cancer (Table 1, Data S1). The majority of the gene signatures
were determined by comparisons of expression patterns with clinical endpoints, and are predicted to
have small overlaps [29]. The pattern of overlaps observed in general fitted this model (Figure S3).
We noted two highly significant sets of overlaps (Figure 1a,b, Figure S3, p < 10−34 for paired overlaps,
hypergeometrical test) involving signatures that were derived using unsupervised approaches or that
involved investigations of particular biological pathways.
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Table 1. Prognostic and Classification gene signatures. Abbreviations are as follows: A, signature
discovered by association with clinically distinct states, B, signature representing a biological
function; U, signature identified by unsupervised approach; LPD, Latent Process Decomposition;
OAS-LPD, One Added Sample-LPD; HCA, Hierarchical Cluster Analysis; ADT, Androgen Deprivation
Therapy; NNMF, Non-Negative Matrix Factorisation; RP, Radical Prostatectomy; PSA Prostate
Specific Antigen.
Citation Year Genes Type Discovery Method Name
Agell et al. 2012 12 A Association to Gleason -
Bibkova et al. 2007 16 A Association to Gleason -
Bismar et al. 2006 12 A Benign vs. Cancer vs. Metastases -
Cuzick et al. 2011 31 B Cell Cycle Genes Prolaris
Erho et al. 2013 22 A Cancers with Different Progressions DECIPHER
Glinksy et al. 2004 11 A PSA Failure vs. No-failure -
Irshad et al. 2013 19 B Aging Genes Altered in Indolent Cancer -
Klein et al. 2014 17 A Association with Outcome OncotypeDX
Lalonde et al. 2014 276 U Genes within Copy Number Changes -
Long et al. 2011 13 A PSA failure vs. No failure -
Luca et al. 2017 45 U LPD DESNT
Luca et al. 2020 49 U OAS-LPD OAS-DESNT
Mo et al. 2018 93 B + A Stroma association to metastasis -
Planche et al. 2011 48 A Normal vs. Tumour differential geneexpression in stroma -
Rajan et al. 2014 7 A Before and After ADT -
Ramos-Montoya et al. 2014 222 B Genes Controlled by HES6 -
Ramaswamy et al. 2003 17 A Metastases vs. Primary -
Ross-Adams et al. 2014 100 U Clustering of Variable Genes -
Sharma et al. 2013 16 B Androgen Receptor Regulated -
Singh et al. 2002 29 A Associated with Gleason -
Varambally et al. 2005 44 A Metastases vs. Primary -
Walker et al. 2017 70 U + A HCA and PLS Regression * -
Wu et al. 2013 32 A Associated with Outcome -
You et al. 2016 428 U NNMF of Control Pathways PCS1, PCS2, PCS3
Yu et al. 2007 7 B Polycomb Repression Signature -
* Applied HCA for subgroup identification and partial-least-squares regression for signature development. All studies
cited are listed in the reference section.
First, there was an overlap between the DESNT genes detected as important by two different LPD
procedures, LPD-DESNT [23] and OAS-LPD DESNT [27], and the gene differentially over-expressed
in the PCS3 subgroup detected by You et al. [26] (p = 2.6 × 10−35 and 2.1 × 10−41; hypergeometrical
test)(Figure 1a, Data S2). In the work of You et al., three groups designated PCS1 (86 genes), PSC2 (123
genes) and PCS3 (219 genes) were detected by non-negative matrix factorisation (NNMF) of the control
pathway status calculated from the observed cancer expression profiles. This match could be considered
as a match to PSC1 because DESNT genes are under-expressed and the genes overexpressed in PCS3
are also under-expressed in PCS1 [26] (Figure S4). This pathway is referred to as SIG-DESNT and the
set of genes within PCS3 that match the DESNT genes is referred to as PCS3-U (U = underexpressed).
Secondly, there was a three-way overlap between the genes associated with PCS1 of You et al. [26],
the Prolaris test genes [19], and the signature of Ramos-Montoya et al. [22] (Figure 1b, Data S3).
The Prolaris genes were chosen based on their role in controlling cell cycle. Ramos-Montoya et al.
selected genes that were controlled by HES6, a transcription factor that has a critical role in driving the
androgen receptor (AR) program. This pathway is referred to as SIG-HES6. The 20 genes within PCS1
matching Prolaris and the HES6 signature are all overexpressed. These genes are referred to as PCS1-O
(overexpressed) and are distinct from the genes overlapping with the DESNT signature (Data S2).
We were interested to compare cancers detected by these two groups of biomarkers (SIG-DESNT
and SIG-HES6) to test whether they are sampling from the same or different cancers at high risk of
PSA failure. To examine high risk cancers detected by NNMF of control pathways, we needed first to
repeat the analyses carried out by You et al.
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Figure 1. Highly significant signature overlaps. (a) Overlaps between LPD DESNT, OAS-LPD DESNT
and PCS3. (b) Overlap between Prolaris, Ramos- ontoya and PCS1 gene signatures. For each pair of
signatures, the probability of the observed overlap occurring by chance was calculated as described in
the materials and methods.
3.2. Cancer Subgroups Identified by Non-Negative Matrix Factorisation of Control Pathways
To repeat the work of You et al. we initially complied and normalised expression profiles from
37 ublic atasets as outlined by the authors (DISC cohort). This resulted in a combine dataset with
linked clinical d ta consisting of primary prostate cancer (n = 1059), non-malignant pros ate tissue
(n = 746), and metastatic samples from men with castration-resistant prostate cancer (n = 254) (Materials
and Meth ds, Figure S1). We sep rately ompiled a validation cohort consisting f prostatectomy
specimens from the MSKCC, CancerMap, CamCap and SWD datasets. For analysis, we used the
14 pathways that were selected by Y u at al. on the basis of their likely involvement in prostate
cance evelopment. cores representing the activation status of e ch pathway in each ampl were
aggregated into a z-sco . Computation of the cophenetic coefficient using a putative number of
subgroups between two and six indicated three as th most likely number of subgroups (Figure 2a,b).
Assignment of samples to the three subgr ups was carried out by NNMF using a 14xN
matrix populated with z-sc r s as a starting point. The results showed that the three subgroups
were detected each ith a distinct pattern of pathway activation (Figure 2c). The three subgroups
were designated NMF1, NMF2 and NMF3. The NMF1 subgroup exhibited overexpression of the
AV, AR-V, PRF, PTEN, ES control pathways, while NMF2 had overexpression of the ERG, AR and
FOXA1 pathways (Figure 2d). NMF3 was characterised by overexpression of the PRC, PN, MES and
RAS pathways. These correspond to the patterns of pathway activation to the three subgroups PCS1,
PCS2 and PSC3, respectively, identified by You et.al. The assignment of the majority of the samples
(94%) was the same (Table S1). However, because of the small differences, a distinct nomenclature is
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used in our study (e.g., NMF1 instead of PCS1). The differences may reflect small deviations in the
datasets and in the methodology used (Materials and Methods).
We identified 262 genes (NMF1 n = 74; NMF2 n = 85; NMF3 n = 103; FDR < 0.0001;
fold-change > 1.4) that were differentially expressed between the three subgroups NMF1, NMF2
and NMF3: 155 of these overlapped with the 428 differentially expressed genes that distinguished
PCS1, PCS2 and PCS3 (Figure S5, Data S4). The overlap between the 262 differentially expressed genes
and DESNT genes remained highly significant (Data S5): OAS-LPD DESNT and NMF3 (13 genes,
p = 2.8 × 10−17; hypergeometrical test); and DESNT and NMF3 (11 genes, p = 2.2 × 10−14).
Finally, a random forest classifier trained on the division into NMF1, NMF2, and NMF3 in
the original dataset was used to interrogate four test datasets (Figure 2e). In each case, there was
a significantly worse outcome for patients assigned to the NMF1 subgroup compared to the NMF2
and NMF3 datasets, consistent with the poor outcome observed for the PCS1 dataset of You et al.
We conclude that we have achieved a similar although not identical stratification of cancer samples
to that achieved by You et al. and that this may be used as a comparator with DESNT cancer and
other stratifications.
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3.3. Overlaps in the Detection of Cancers at High Risk of PSA Failure
Returning to the comparisons of cancers detected by the SIG-DESNT and SIG-HES6 groups of
signatures, we combined data from the CancerMap, CamCap and MSKCC datasets (n = 482 patients)
with PSA failure as an end point, and then separately applied the DESNT, HES6, NMF1, and Prolaris
tests. DESNT is calculated as a continuous variable designated γ representing the proportion of the
analysed sample that contains the DESNT signature. Cancers were assigned as a “DESNT cancer”
when this gene expression pattern had a larger γ value than any other contributing signatures. Random
forest classifiers were used to detect NMF1 and Ramos-Montoya et al. high-risk cancers (Figure S2e–g).
We used a published formula to calculate the Prolaris index [19] and selected the 25% of cancers
exhibiting highest risk.
Based on the assumption that each of the two signature groups (SIG-DESNT and SIG-HES6)
represents a separate underlying molecular mechanism, there are two predicted results. Each signature
group could represent an entirely separate progression mechanism in which case two non–overlapping
groups of cancers with PSA failures should be detected. Alternatively, the two underlying mechanisms
may cooperate to cause cancer progression, meaning that the SIG-DESNT and SIG-HES6 predictors
will detect the same or overlapping groups cancers with PSA failure.
The overlaps in memberships of each group at high risk of PSA failure are shown in Figure 3
supporting the second of these models. A total of 30 cancers were assigned as high risk by all of the
prognostic makers and of these 20 had undergone PSA failure (66.7%). Of 100 cancers with 50 PSA
failures assigned the SIG-DESNT signature (DESNT), 61(37 PSA failures) were also detected by at
least one of the SIG-HES6 signatures (HES6, Prolaris, and/or NMF1) (Figure 3). A combination of the
Ramos-Montoya et al. (SIG-HES6) and DESNT (SIG-DESNT) models predicted the majority of PSA
failures present in the high-risk cancer groups (76 of 84, 90.5%), with 32 failures overlapping.Genes 2020, 11, x FOR PEER REVIEW 9 of 15 
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Figure 3. Detection of high-risk cancers. For each sa ple in the combined dataset obtained by merging
the CamCap, CancerMap and MSKCC datasets, we determined whether the patient was deemed high
risk using four biomarkers: NMF1, Prolaris, Ramos-Monotoya et al. and DESNT. (a) The intersections
between the four high-risk categories. The samples in brackets indicate the number of PSA failures.
NMF refers to NMF1. (b) Kaplan–Meier plot when patients are grouped by the number of biomarkers
that indicate that they are high risk. Endpoint is the time to biochemical recurrence. (c) Kaplan–Meier
plot when patients are grouped by whether they are deemed high risk for DESNT, for at least one of the
component biomarkers of SIG-HES6, or for both.
Kaplan–Meier analyses were preformed to investigate the interactions between the high-risk
categories. A particularly poor outcome was observed for patients designated as high risk by all four
biomarkers (Figure 3b). Looking at the interactions between SIG-HES6 and SIG-DESNT biomarkers,
we found int rmediate rates of progression for pa ients deem d high risk ither for DESNT (p = 0.0037
Benjamini–Hochberg adjuste for multiple testing (BH); pairwise comparison between DESNT only
and neither; 26.9 vs. 93.0 months to 25% events) or for at least one of the SIG-HES6 biomarkers
(Prolaris and/or PCS1 and/or Ramos-Monotoya et al.) (BH p = 0.0039; 42.5 vs. 93.0 months to 25% events;
Figure 3c). However, when patients were designated as high risk both by DESNT and by at least one
of the SIG-HES6 biomarkers, their outc me was considerably worse (Time to 25% events = 8.0 months;
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BH p < 2 × 10−16 both vs. neither; Figure 3c). This observation is consistent with our hypothesis
that two underlying mechanisms represented by SIG-HES6 and SIG-DESNT are interacting to cause
cancer progression.
Upon investigation of whether poor outcome was simply determined by Gleason Score, we found
that the number of signatures that indicated that a patient was at high risk was an independent
prognostic indicator when Gleason was included as a covariate (IQR HR = 1.98; 95% CI 1.54–2.55;
p = 1.01 × 10−7; Cox proportional hazards regression model). In additional, the combination of a high
risk defined by at least one member of SIG-HES6 and DESNT is an independent prognostic indicator
when Gleason is included as a covariate [HR = 3.86 (95% CI 2.41–6.19)]. This compares to DESNT only
[HR = 1.85 (0.99–3.46)], and SIG-HES6 only [HR = 1.61 (95% CI 1.02–2.52)] (Cox proportional hazards
regression models). These results show that designation as high risk provides additional prognostic
information to that determined by Gleason Score.
3.4. Comparison of DESNT and Non-Negative Matrix Factorisation Subgroups
We wished to further investigate the relationship between the DESNT and NMF1 poor prognosis
groups. To achieve this, the MSKCC, CancerMap, CamCap, and TCGA datasets were combined and
DESNT was plotted as a continuous variable (DESNT γ), as described in Luca et al. [27]. DESNT γ was
significantly higher in NMF1 cancers compared to NMF2 and NMF3 cancers (Figure 4a) and the results
of Gene Set Enrichment Analysis (GSEA) analysis show a highly significant association (p < 1 × 10−6),
giving an enrichment score of 0.61 (Figure 4b).
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We next calculated pathway status (z-scores, as shown in Figure 2b) for all samples in the MSKCC,
CancerMap, CancerMap and TCGA datasets and grouped the samples according to NMF1 and DESNT
status. The results are shown in Figure 4c. Cancers assigned both as DESNT and NMF1 had the
strongest association with time to progression (Figure 4d, p = 4.4 × 10−16, Log-rank test) followed
by DESNT-non-NMF1 cancers (p = 4.19 × 10−7) and non-DESNT-NMF1 cancers (p = 1.45 × 10−2).
Membership of DESNT accounted for 36% (31/86) of NMF1 cancers in this series but 59% (31/45) of its
PSA failures. Notably, activation of the PTEN, ES, AR-V, PRF and EZH2 pathways, a feature of NMF1
cancers, was not present in DESNT-non-NMF1 cancers.
We conclude from these studies that NMF1 and DESNT are overlapping but distinct
cancer categories.
4. Discussion
A number of critical observations arise from the presented studies. Signatures derived by
comparisons of expression profiles to clinical features (e.g., to Gleason Score and to PSA failure)
exhibited only modest overlaps in gene lists. This was exactly as predicted from previous analyses of
breast cancer datasets [29]. When normal cells change into a cancer cells or when the clinical state
of a cancer is altered, many thousands of genes may exhibit altered expression levels and multiple
control pathways modulated. Based only on the analyses performed to identify these biomarkers, it is
not possible to determine whether the genes identified are central to cancer development or represent
secondary events. Nonetheless, when biomarker analyses are combined with additional studies, useful
individual genes are highlighted. For example, HOXB13 was identified in expression array studies as
a gene highly upregulated in prostate cancer [48] but its central importance to cancer development was
not established until the analyses of cancer families were performed [49]. AMACR was first identified
as a gene upregulated in three of four expression array datasets from prostate cancer, but its importance
as a cancer marker was not recognised until immunohistochemical studies of tissue sections were
performed [50].
When significant overlaps do occur between predictive gene lists developed using entirely different
approaches, it is our belief that this indicates genes fundamental for controlling cancer progression.
The observation that HES6-signature reported by Ramos-Montoya et al. [22] overlaps with the PCS1 [26]
and Prolaris [19] signatures supports this view. HES6 drives castration-resistant tumour growth by
enhancing the transcriptional activity of the androgen receptor, while the Prolaris signature contains
many genes known to be critical for cell cycle control—both processes already known to be essential
for prostate cancer growth. A second overlap occurred between downregulated DESNT genes [23,27]
and a set of genes overexpressed in PCS3 [26]. We propose that genes from these two categories are
also involved in processes fundamental to the development of prostate cancer. The precise mechanism
is currently unknown, although possible but different models were suggested both by Luca et al. [23]
and by You et al. [26].
Support for this model was obtained from analyses of the impact of DESNT and SIG-HES6
signatures on clinical outcome. When patients were designated as poor prognosis by DESNT and by
one or more of the SIG-HES6 signatures (Prolaris, PCS1, Ramos-Montoya et al.), a considerably worse
outcome was observed compared with use of DESNT or SIG-HES6 signatures alone, consistent with
interaction. This observation also has implications for patient management, indicating that use of
DESNT classification together with, for example, the Prolaris biomarker or the Ramos-Montoya et al.
biomarker could greatly increase the ability to predict whether a patient with organ-confined prostate
cancer will progress following treatment. This would allow targeting of treatment to the patients who
need it hence avoiding the side effects, including impotence, of unnecessary treatment in men with
indolent disease.
The overlapping signature DESNT, PCS3, HES6, Prolaris and PCS3 are all derived using
unsupervised approaches or by investigation of biological function. It is of interest that not all
signature derived using these approaches demonstrated highly significant overlaps. The derivation of
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the 70-gene biomarker proposed by Walker et al. [25] represent an interesting case. A 222-gene signature
was originally generated using an unsupervised approach. The 70-gene signature represents a subset
of these genes derived by a combination of unsupervised and supervised approaches. We failed to
observe highly significant overlaps involving this signature (Figure S3). Additional signatures involving
unsupervised steps that failed show gene overlaps includes those derived by Lalonde et al. [28] and
by Ross Adams et al. [24].
We provide evidence that classifications based on NNMF analysis of control pathways and the
DESNT classification are overlapping but distinct. The methods of clinical applications of the two tests
are also different. Assignment to the PCS1 poor prognosis category is based on the use of a classifier of
37-gene classifier [26] selected from genes’ differential expression between the PCS1, PCS2, and PCS3
groups. In contrast, the poor prognosis DESNT signature is only considered to be present in part of the
cancer, with the exact proportion (or DESNT γ) calculated by LPD carried out on genes with the most
variable levels of expression across samples [23,27]—the DESNT gene signature itself cannot be used
to calculate outcome. Once calculated, the proportion of DESNT cancer can be used in a nomogram
together with clinical variables to estimate likelihood of PSA failure [27]. Additionally, PCS1 and PCS3
had been assigned as having, respectively, luminal and basal phenotypes based on the expression of
a set of 12 genes [26]. In contrast, we failed to find differential expression of these same genes when
comparing DESNT and non-DESNT cancers (result not shown).
An important finding is that all of the highly overlapping signatures predicting poor outcome
appear to be sampling from the same high-risk cancer group: the SIG-HES6-and SIG-DESNT groups of
signatures are not detecting entirely separate groups of high-risk cancers. This result as well as the
observed interactions between DESNT and SIG-HES6 signatures in identifying patients with poor
outcome are both consistent with a model where underlying molecular processes represented by
SIG-HES6 and SIG-DESNT interact, leading to aggressive disease. This observation may have relevance
to approaches for therapeutic targeting. In the clinical setting, the HES6-associated signature can be
pharmacologically targeted by inhibition of PLK1 with restoration of sensitivity to castration [22].
For the DESNT signature, many of the genes with downregulated expression in prostate cancer are
hypermethylation [23], indicating that 5-azacytidine that could be used to enhance gene expression.
Thus, a prediction of the current studies is that the combined use of inhibitors of HES6 function,
androgen withdrawal and strategies for gene re-expression, would synergise in preventing the growth
of castration-sensitive prostate cancer. Our results also have an implication for the use of biomarkers
in general since the use of DESNT together with a SIG-HES6 biomarker may represent a much more
effective method for detecting patients with aggressive disease.
5. Conclusions
To our knowledge this is the first publication to systematically analyze the relationships between
multiple distinct prognostic signatures for prostate cancer. We start with the hypothesis that highly
significant overlaps between signatures derived using different approaches indicates genes and
processes fundamental to prostate cancer progression; leading to the identification of two sets of
overlaps designated SIG-HES6 and SIG-DESNT. First, we conclude that our results support a model
whereby SIG-HES6 and SIG-DESNT genes co-operated to cause cancer progression. Secondly, consistent
with this model, the use of a SIG-HES6 signature in combination with DESNT provides a much better
predictor of poor outcome than the use of either alone. Thirdly, for the drug treatment of patients
we predict a synergy between (i) inhibitors of HES6 function, and (ii) agents, such as 5-azacytidine,
that can induce re-expression of DESNT genes.
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